CY2013008I1 - Πεπτιδιο κατασταλτικο της ορεξης, συνθεσεις και χρηση αυτου - Google Patents

Πεπτιδιο κατασταλτικο της ορεξης, συνθεσεις και χρηση αυτου

Info

Publication number
CY2013008I1
CY2013008I1 CY2013008C CY2013008C CY2013008I1 CY 2013008 I1 CY2013008 I1 CY 2013008I1 CY 2013008 C CY2013008 C CY 2013008C CY 2013008 C CY2013008 C CY 2013008C CY 2013008 I1 CY2013008 I1 CY 2013008I1
Authority
CY
Cyprus
Prior art keywords
compositions
appetite suppressant
peptide
suppressant peptide
appetite
Prior art date
Application number
CY2013008C
Other languages
English (en)
Other versions
CY2013008I2 (el
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26063575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2013008(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of CY2013008I1 publication Critical patent/CY2013008I1/el
Publication of CY2013008I2 publication Critical patent/CY2013008I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CY2013008C 1996-03-01 2013-02-27 Πεπτιδιο κατασταλτικο της ορεξης, συνθεσεις και χρηση αυτου CY2013008I2 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK23196 1996-03-01
DK23096 1996-03-01
EP01122701A EP1231218B1 (en) 1996-03-01 1997-02-27 An appetite-suppressing peptide, its compositions and use
EP97905000A EP0891378B1 (en) 1996-03-01 1997-02-27 Use of a pharmaceutical composition comprising an appetite-suppressing peptide

Publications (2)

Publication Number Publication Date
CY2013008I1 true CY2013008I1 (el) 2015-08-05
CY2013008I2 CY2013008I2 (el) 2015-08-05

Family

ID=26063575

Family Applications (2)

Application Number Title Priority Date Filing Date
CY201200011A CY2619B2 (el) 1996-03-01 2012-10-12
CY2013008C CY2013008I2 (el) 1996-03-01 2013-02-27 Πεπτιδιο κατασταλτικο της ορεξης, συνθεσεις και χρηση αυτου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY201200011A CY2619B2 (el) 1996-03-01 2012-10-12

Country Status (22)

Country Link
EP (4) EP1975177B1 (el)
JP (1) JP4064460B2 (el)
KR (1) KR100611130B1 (el)
CN (1) CN1112367C (el)
AT (3) ATE395359T1 (el)
AU (1) AU710818B2 (el)
BR (1) BR9707807A (el)
CA (1) CA2246733C (el)
CY (2) CY2619B2 (el)
CZ (1) CZ297338B6 (el)
DE (3) DE69738695D1 (el)
DK (2) DK0891378T3 (el)
ES (3) ES2187756T3 (el)
FR (1) FR13C0009I2 (el)
HU (1) HU229234B1 (el)
IL (1) IL125805A0 (el)
NO (2) NO323043B1 (el)
PL (1) PL187095B1 (el)
PT (1) PT1975177E (el)
RU (1) RU2197261C2 (el)
UA (1) UA70283C2 (el)
WO (1) WO1997031943A1 (el)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
EP1975177B1 (en) * 1996-03-01 2011-04-13 Novo Nordisk A/S An appetite-suppressing peptide, its compositions and use
AU733857B2 (en) 1996-04-12 2001-05-31 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69732572T2 (de) * 1996-11-12 2005-12-29 Novo Nordisk A/S Verwendung von glp-1 peptiden
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
ES2222613T3 (es) * 1997-09-12 2005-02-01 Pharis Biotec Gmbh Composicion para la terapia de diabetes mellitus y de la obesidad.
CA2312190A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
WO1999043361A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
JP2002506792A (ja) * 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
JP2002508162A (ja) * 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
AU3087599A (en) * 1998-03-19 1999-10-11 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
EP1970072A1 (en) * 2000-09-18 2008-09-17 Sanos Bioscience A/S Use of GLP-2 peptides for the treatment of hyperparathyroidism
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7090869B2 (en) 2000-12-01 2006-08-15 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive substance
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
ATE502665T1 (de) 2003-02-04 2011-04-15 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
EP2298337B1 (en) 2003-12-09 2017-02-22 Novo Nordisk A/S Regulation of food preference using GLP-1 agonists
DK2842576T3 (en) 2004-01-21 2017-10-16 Novo Nordisk Healthcare Ag Transglutaminase-mediated peptide conjugation
PL1729795T3 (pl) 2004-02-09 2016-08-31 Human Genome Sciences Inc Białka fuzyjne albuminy
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
MXPA06011924A (es) * 2004-04-15 2007-06-11 Alkermes Inc Dispositivo de liberacion continua base polimeros.
EP2316446A1 (en) 2004-06-11 2011-05-04 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
UA95235C2 (en) 2005-05-04 2011-07-25 Зииланд Фарма А/С Glucagon-like-peptide-2 (glp-2) analogues
ES2397289T3 (es) 2005-09-22 2013-03-06 Biocompatibles Uk Ltd. Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
DE602006009631D1 (de) 2006-05-10 2009-11-19 Biocompatibles Uk Ltd GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
CN101573376B (zh) 2006-11-08 2013-11-06 西兰制药公司 选择性胰高血糖素样肽-2（glp-2）类似物
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US20100278843A1 (en) * 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2872315A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR101576126B1 (ko) 2014-12-29 2015-12-11 부경대학교 산학협력단 αＡＬ１４ 펩타이드를 유효성분으로 함유하는 신규 비만 예방 및 치료용 약학적 조성물
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
MX2017015504A (es) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Sistemas de colocacion y remoción de implante.
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
SG11201903938XA (en) 2016-12-09 2019-05-30 Zealand Pharma As Acylated glp-1/glp-2 dual agonists
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
AU2020268087A1 (en) * 2019-05-06 2021-11-25 The University Of Sydney Methods for the fractionation of proteins

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
DE3382547D1 (de) 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
JPS60501140A (ja) 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
WO1987002670A1 (en) 1985-10-25 1987-05-07 Mackay Vivian L Method of using bar1 for secreting foreign proteins
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
DE3856247T2 (de) 1987-07-24 1999-04-29 Chiron Corp Züchtung von insektenzellen mit airlift-reaktoren
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
WO1990005783A1 (en) 1988-11-18 1990-05-31 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP1975177B1 (en) * 1996-03-01 2011-04-13 Novo Nordisk A/S An appetite-suppressing peptide, its compositions and use

Also Published As

Publication number Publication date
DE69738695D1 (de) 2008-06-26
EP0891378B1 (en) 2002-11-13
NO984005L (no) 1998-08-31
ES2306685T3 (es) 2008-11-16
ATE505485T1 (de) 2011-04-15
EP1231218A3 (en) 2002-10-30
EP0891378A1 (en) 1999-01-20
KR19990087439A (ko) 1999-12-27
ATE227737T1 (de) 2002-11-15
DK0891378T3 (da) 2003-01-06
CA2246733C (en) 2010-07-20
CZ297338B6 (cs) 2006-11-15
EP1975177A1 (en) 2008-10-01
DE69717092T2 (de) 2003-07-24
AU710818B2 (en) 1999-09-30
FR13C0009I1 (el) 2013-03-22
CY2013008I2 (el) 2015-08-05
DE69717092D1 (de) 2002-12-19
CA2246733A1 (en) 1997-09-04
ES2364705T3 (es) 2011-09-12
JP2000505460A (ja) 2000-05-09
HU229234B1 (en) 2013-09-30
NO984005D0 (no) 1998-08-31
EP1975177B1 (en) 2011-04-13
EP1231218B1 (en) 2008-05-14
CN1112367C (zh) 2003-06-25
UA70283C2 (en) 2004-10-15
NO2013006I2 (el) 2013-03-12
CZ273698A3 (cs) 1998-12-16
WO1997031943A1 (en) 1997-09-04
BR9707807A (pt) 1999-07-27
DK1975177T3 (da) 2011-07-25
PL187095B1 (pl) 2004-05-31
DE69740176D1 (de) 2011-05-26
NO2013006I1 (no) 2013-04-02
PT1975177E (pt) 2011-07-26
FR13C0009I2 (fr) 2013-08-16
IL125805A0 (en) 1999-04-11
NO323043B1 (no) 2006-12-27
EP2295453A2 (en) 2011-03-16
EP2295453A3 (en) 2011-03-30
CN1215405A (zh) 1999-04-28
PL328732A1 (en) 1999-02-15
JP4064460B2 (ja) 2008-03-19
AU1871597A (en) 1997-09-16
ATE395359T1 (de) 2008-05-15
RU2197261C2 (ru) 2003-01-27
CY2619B2 (el) 2013-03-13
ES2187756T3 (es) 2003-06-16
EP1231218A2 (en) 2002-08-14
KR100611130B1 (ko) 2006-11-30
HUP9902670A3 (en) 2000-02-28

Similar Documents

Publication Publication Date Title
CY2013008I2 (el) Πεπτιδιο κατασταλτικο της ορεξης, συνθεσεις και χρηση αυτου
HUP0100100A3 (en) Hepatitis c inhibitor peptide analogues, pharmaceutical compositions comprising thereof and their use
BR9702553A (pt) Composição cosmética e utilização
BR9607317A (pt) Peptídios e composição farmacêutica
BR9607318A (pt) Peptidos e composição farmacêutica
PT1120392E (pt) Catalisador e composicao organometalica
PT881906E (pt) Composicao farmaceutica para a imunomodelacao baseada em peptideos e adjuvantes
BR9504791B1 (pt) composto de polipeptìdeo e composição farmacêutica.
EE9900497A (et) Söögiisu pärssiva toimega farmatseutilised kompositsioonid
NO20003254D0 (no) Anti-østrogene steroider og farmasøytisk preparat inneholdende samme, samt anvendelse derav
PT941056E (pt) Composicoes de esfingomielinase e sua utilizacao
BR9708400A (pt) Composição sua preparação e uso
NL300295I1 (nl) 3,3-Diarylpropylaminen, de toepassing en bereiding hiervan
HU0500549D0 (en) Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
CY2009008I1 (el) Gnrh ανταγωνιστες τροποποιημενοι στις θεσεις 5 και 6
HUP0100149A3 (en) Antipicornaviral peptide derivatives pharmaceutical compositions comprising thereof and their use
DK0804078T3 (da) Sammensætning og anvendelse deraf
BR9707691A (pt) Peptídios antipatogênicos e composições que compreendem os mesmos
DE69724629D1 (de) Zusammensetzungen und deren verwendungen
NO20004274L (no) Proteaseaktivert reseptor 4 og anvendelse derav
DE69724367D1 (de) Polyarylensulfid und zusammensetzung
BR9509688A (pt) Composto e composição farmacêutica
DE69634489D1 (de) Adenovirus dodekahedrischer proteinkomplex, dieser enthaltende zusammensetzung und verwendungen davon
PT811593E (pt) Agentes insecticidas e acaricidas 1,4-diaril-2-fluor-2-buteno
NL1007839A1 (nl) Formulering en gebruik.